Indication
Lymphangioleiomyomatosis
9 clinical trials
8 products
5 drugs
Clinical trial
TSC Alliance Tuberous Sclerosis Complex (TSC) Biosample Repository and Natural History DatabaseStatus: Recruiting, Estimated PCD: 2050-12-01
Product
Genetic TestingClinical trial
Multicenter Interventional Lymphangioleiomyomatosis (LAM) Early Disease TrialStatus: Recruiting, Estimated PCD: 2025-06-30
Product
SirolimusClinical trial
Multicenter International Lymphangioleiomyomatosis Efficacy and Safety of Sirolimus TrialStatus: Completed, Estimated PCD: 2010-09-01
Product
PlaceboClinical trial
Bronchodilator Effects of Nebulized Versus Inhaled Albuterol in Subjects With LymphangioleiomyomatosisStatus: Recruiting, Estimated PCD: 2026-11-01
Product
AlbuterolClinical trial
Trial of Letrozole in LymphangioleiomyomatosisStatus: Completed, Estimated PCD: 2014-09-01
Drug
TucidinostatDrug
VarlilumabClinical trial
Resveratrol and Sirolimus in Lymphangioleiomyomatosis Trial (RESULT)Status: Completed, Estimated PCD: 2022-10-15
Drug
rapamycinProduct
ResveratrolClinical trial
Feasibility Study of [11C]Acetate Positron Emission Tomography (PET) as an Indicator of Early Response to Rapamycin in Lymphangioleiomyomatosis (LAM) PatientsStatus: Recruiting, Estimated PCD: 2023-08-30
Product
[11C]acetateClinical trial
Discovery of Sirolimus Sensitive Biomarkers in BloodStatus: Recruiting, Estimated PCD: 2025-09-30
Clinical trial
A Phase I Trial of Bevacizumab, Temsirolimus Alone and in Combination With Valproic Acid, or Cetuximab in Patients With Advanced Malignancy and Other IndicationsStatus: Active (not recruiting), Estimated PCD: 2026-03-31
Drug
AtezolizumabDrug
cetuximabProduct
TemsirolimusProduct
Valproic Acid